KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Return on Equity (2016 - 2025)

Historic Return on Equity for NovoCure (NVCR) over the last 11 years, with Q3 2025 value amounting to 0.51%.

  • NovoCure's Return on Equity fell 1000.0% to 0.51% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.51%, marking a year-over-year decrease of 1000.0%. This contributed to the annual value of 0.47% for FY2024, which is 500.0% up from last year.
  • NovoCure's Return on Equity amounted to 0.51% in Q3 2025, which was down 1000.0% from 0.48% recorded in Q2 2025.
  • NovoCure's Return on Equity's 5-year high stood at 0.03% during Q1 2021, with a 5-year trough of 0.55% in Q4 2023.
  • Over the past 5 years, NovoCure's median Return on Equity value was 0.41% (recorded in 2023), while the average stood at 0.31%.
  • As far as peak fluctuations go, NovoCure's Return on Equity crashed by -3400bps in 2023, and later soared by 800bps in 2024.
  • NovoCure's Return on Equity (Quarter) stood at 0.14% in 2021, then crashed by -47bps to 0.21% in 2022, then tumbled by -162bps to 0.55% in 2023, then rose by 15bps to 0.47% in 2024, then fell by -10bps to 0.51% in 2025.
  • Its Return on Equity was 0.51% in Q3 2025, compared to 0.48% in Q2 2025 and 0.45% in Q1 2025.